Further to letter dated 14th December 2022 and in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Aurobindo Pharma has informed that it enclosed a copy of the Postal Ballot Notice dated 14th December, 2022 together with the Explanatory Statement thereto, seeking approval of the Members to reappoint Girish Paman Vanvari (DIN: 07376482) as an Independent Director of the Company for a second term of five consecutive years from 5th November 2022 to 4th November, 2027. In accordance with the applicable laws and circulars thereunder, the Postal Ballot Notice is being sent in electronic mode to those Members whose names appear on the Register of Members/ List of Beneficial Owners as on Friday, 16th December 2022, being the cut-off date for the purpose, and whose email address is registered with KFin Technologies, the Company’s Registrar and Share Transfer Agent or Depository Participants, and in physical form to those Members whose email address is not so registered. The Notice is also available on the website of the Company: www.aurobindo.com and website of KFintech at https://evoting.kfintech.com. Members whose names appeared in the Register of Members / List of Beneficial Owners as on the cut-off date, Friday, December 14, 2022 are eligible for voting. The remote e-voting will commence from Friday, 23rd December 2022 (9.00 am IST) and will end on Saturday, 21st January 2023 (5.00 pm IST). The results of the Postal Ballot will be announced on or before Tuesday, 24th January 2023.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: